Background and Aims: Breast cancer with morphological classification has limitation with similar clinical and histological features behave differently regarding prognosis and therapy response. Hence the molecular classification has been introduced to predict the clinical
outcome. The aim of this study were to classify breast cancer into various molecular subtypes using surrogate IHC biomarkers such as ER, PR, Her2/neu and to find the correlation of each subtype with clinicopathological features.
Materials and Methods: A total one hundred and twelve cases were enrolled in the study. The surgical specimens were evaluated histopathologycally; Suitable block was subjected for immunostain (ER, PR and Her2/neu). Based on their expression status molecular phenotyping was done.
Statistical Analysis Used: All the data were analysed with chi square test by SPSS Statistics Version 23.0. Armonk, NY: IBM Corp software.
Results: The mean age of the patient was 51.11 ± 12 years. Most common histological type was invasive ductal carcinoma, no special type (84.8%). Tumor size with <5 cm (68%) and left laterality (60%) being the most prevalent. Majority of cases were in Grade II and pT2 category. Molecular subtypes had following distribution: Basal like and luminal B were accounted 30% each, while luminal A and Her2/neu enriched were 20% each respectively. There was an association between tumour grade with molecular subtypes and ER, PR receptor expression status with significant p-value.
Conclusions: Incorporation of molecular subtyping into traditional histopathological reporting help in better therapeutic management and increases prognostic accuracy. In the current study Basal like presented in advanced stage of their disease.
Keywords: Invasive ductal carcinoma; Luminal subtypes; Prognostic markers.